Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B et al. Drug Des Devel Ther. 2016 Jan 11;10:217-26. doi: 10.2147/DDDT.S93602. eCollection 2016.
Immune Checkpoint Blockade in Lymphoid Malignancies.
Thanarajasingam G et al, FEBS J. 2016 Jan 25. doi: 10.1111/febs.13668. [Epub ahead of print].
Elotuzumab: First Global Approval.
Markham A. Drugs. 2016 Jan 26. [Epub ahead of print].
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström’s macroglobulinemia.
Ghobrial IM et al. Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24300. [Epub ahead of print].
Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
Atanackovic D et al. Br J Haematol. 2016 Jan 20. doi: 10.1111/bjh.13889. [Epub ahead of print].
Chimeric Antigen Receptor T Cells in Myeloma.
Garfall AL et al. N Engl J Med. 2016 Jan 14;374(2):194. doi: 10.1056/NEJMc1512760.
Chimeric Antigen Receptor T Cells in Myeloma.
Shimabukuro-Vornhagen A et al. N Engl J Med. 2016 Jan 14;374(2):193-4. doi: 10.1056/NEJMc1512760#SA1.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S et al. Lancet. 2016 Jan 6. pii: S0140-6736(15)01120-4. doi: 10.1016/S0140-6736(15)01120-4. [Epub ahead of print].
Daratumumab in multiple myeloma.
Rajkumar SV. Lancet. 2016 Jan 6. pii: S0140-6736(15)01226-X. doi: 10.1016/S0140-6736(15)01226-X. [Epub ahead of print].
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.
Moreau P et al. Leuk Lymphoma. 2016 Jan 12:1-14. [Epub ahead of print].
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Watanabe T et al. Br J Haematol. 2016 Jan 5. doi: 10.1111/bjh.13900. [Epub ahead of print].
Age of antibody therapeutics dawns for multiple myeloma.
Kingwell K et al. Nat Rev Drug Discov. 2015 Dec 31;15(1):5-6. doi: 10.1038/nrd.2015.39.
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.
Yong K et al. Br J Cancer. 2016 Jan 12;114(1):7-13. doi: 10.1038/bjc.2015.422. Epub 2015 Dec 22